ALID - Allied Corp Announces Strategic Commercial Team Expansion to Accelerate Global Sales
(TheNewswire)
Kelowna, BC, Canada – TheNewswire - September 27,2023 - Allied Corp . ("Allied" or the“Company”) ( OTC:ALID ), a leading player in theinternational cannabis industry, is thrilled to announce a significantexpansion of its commercial team, marking a crucial step forward inthe company's mission. Recognizing its competitive edge, Allied Corpis dedicated to advancing the presence of its Colombian grown cannabisto the international sphere.
To support this vision and expand their reach, theCompany has made strategic additions to its commercial teamincluding:
Chief Business Development Officer(CBDO). Michael Moses, an entrepreneur withexecutional expertise in go-to-market, business strategy andpartnership building, has been appointed as the new CBDO of AlliedCorp. With experience in working with engineering, investment and riskmanagement firms from across three continents, Moses brings a strongunderstanding of the business needs relating to taking products tomarket. His expertise, along with his network in the Cannabisindustry, will be instrumental in identifying new opportunities anddriving growth for the company.
Vice President of GlobalSales. Allied Corp is also pleased towelcome Juba Hadid as the Global VP of Sales. Hadid has a decade ofexperience in leading successful sales teams across multiple regionshaving lived in six different countries himself. His successes atGartner while working in supply chain with big pharma companies suchas Pfizer, Amgen and Sanofi make him favoured for this newchapter. With a focus on expanding Allied Corp's footprint ininternational markets, Hadid will play a pivotal role in buildingdurable relationships with strategic partners, clients, and diversechannels, thus growing Allied Corps commercial footprint.
Contracted a Cannabis Sales andGo-To-Market Consulting Group. Allied Corp hasengaged a highly specialized medical cannabis sales company. Thecompany boasts an in-depth understanding of cannabis supply chains,regulatory frameworks, and an extensive B2B sales network in severalinternational markets. This strategic collaboration is set to equipand guide Allied Corp’s sales efforts while validating and extendingits go-to-market strategy for an appropriate targeted approach.
This expansion of the commercial efforts reflectsAllied Corp's commitment to achieving sustainable growth anddelivering top-quality cannabis products and solutions to customersworldwide.
Allied Corp is excited about the opportunities thisexpansion brings and is confident that the combined expertise of thenew team members and strategic partnerships will help the companyreach new heights in the global cannabis market.
About Allied Corp.
AlliedCorp. is aninternational cannabis company with its main production center inColombia and is one of the few companies that has exported fromColombia internationally and the first company to export commercialcannabis flower from Colombia. By leveraging the Colombian advantages,Allied offers consistent supply of premium cannabis product at scaleand attractive prices, while meeting high quality standards, thussignificantly de-risking its partners supply chain.
InvestorRelations:
1-877-255-4337
Forward-LookingStatements:
This press release contains“forward-looking information” within the meaning of applicablesecurities laws in Canada or the United States ( “forward-lookinginformation”). Forward-looking information may relate to theCompany’s future outlook and anticipated events, plans or results,and may include information regarding the Company’s objectives,goals, strategies, future revenue or performance and capitalexpenditures, and other information that is not historicalinformation. Forward-looking information can often be identified bythe use of terminology such as “believe,” “anticipate,”“plan,” “expect,” “pending,” “in process,”“intend,” “estimate,” “project,” “may,” “will,”“should,” “would,” “could,” “can,” the negativesthereof, variations thereon and similar expressions. Theforward-looking information contained in this press release is basedon the Company’s opinions, estimates and assumptions in light ofmanagement’s experience and perception of historical trends, currentconditions and expected future developments, as well as other factorsthat management currently believes are appropriate and reasonable inthe circumstances. Forward looking statements in this press releaseinclude the following: that Allied is leveraging the conditions in itsColombia grow operation and future Kelowna location to support itsResearch and Development efforts; that Allied is making importantstrides forward to position itself as a leader in the medical cannabisspace, that Allied intends to make a series of proposed trademark andother intellectual property protection filings, as part of theCompany’s Intellectual Property and Pharma Development (IP&PD)Strategy, statements respecting the joint development, manufacturing,and the introduction of TACTICAL RELIEF™ brandedproducts.
There can be no assurance that theunderlying opinions, estimates and assumptions will prove to becorrect. Risk factors that could cause actual results to differmaterially from forward-looking information in this release include:the Company’s exposure to legal and regulatory risk; the effect ofthe legalization of adult-use cannabis in Canada and Colombia on themedical cannabis industry is unknown and may significantly andnegatively affect the Company’s medical cannabis business; that themedical benefits, viability, safety, efficacy, dosing and socialacceptance of cannabis are not as currently expected; that adversechanges or developments affecting the Company’s main or plannedfacilities may have an adverse effect on the Company; that the medicalcannabis industry and market may not continue to exist or develop asanticipated or the Company may not be able to succeed in this market;risks related to completion of the greenhouse construction inColombia, risks related to market competition; risks related to theproposed adult-use cannabis industry and market in Canada and Colombiaincluding the Company’s ability to enter into or compete in suchmarkets; that the Company has a limited operating history and ahistory of net losses and that it may not achieve or maintainprofitability in the future; risks related to the Company’s currentor proposed international operations; risks related to future thirdparty strategic alliances or the expansion of currently existingrelationships with third parties; that the Company may not be able tosuccessfully identify and execute future acquisitions or dispositionsor successfully manage the impacts of such transactions on itsoperations; risks inherent to the operation of an agriculturalbusiness; that the Company may be unable to attract, develop andretain key personnel; risks resulting from significant interruptionsto the Company’s access to certain key inputs such as raw materials,electricity, water and other utilities; that the Company may be unableto transport its cannabis products to patients in a safe and efficientmanner; risks related to recalls of the Company’s cannabis productsor product liability or regulatory claims or actions involving theCompany’s cannabis products; risks related to the Company’sreliance on pharmaceutical distributors; that the Company, or thecannabis industry more generally, may receive unfavorable publicity orbecome subject to negative consumer or investor perception; thatcertain events or developments in the cannabis industry more generallymay impact the Company’s reputation or its relationships withcustomers or suppliers; that the Company may not be able to obtainadequate insurance coverage in respect of the risks that it faces,that the premiums for such insurance may not continue to becommercially justifiable or that there may be coverage limitations andother exclusions which may result in such insurance not beingsufficient; that the Company may become subject to liability arisingfrom fraudulent or illegal activity by its employees, contractors,consultants and others; that the Company may experience breaches ofsecurity at its facilities or losses as a result of the theft of itsproducts; risks related to the Company’s information technologysystems; that the Company may be unable to sustain its revenue growthand development; that the Company may be unable to expand itsoperations quickly enough to meet demand or manage its operationsbeyond their current scale; that the Company may be unable to secureadequate or reliable sources of necessary funding; risks related to,or associated with, the Company’s exposure to reportingrequirements; risks related to conflicts of interest; risks related tofluctuations in foreign currency exchange rates; risks related to theCompany’s potential exposure to greater-than-anticipated taxliabilities; risks related to the protection and enforcement of theCompany’s intellectual property rights, or the intellectual property that it licensesfrom others; that the Company may become subject to allegations thatit or its licensors are in violation of the intellectual propertyrights of third parties; that the Company may not realize the fullbenefit of the clinical trials or studies that it participates in;that the Company may not realize the full benefit of its licenses ifthe licensed material has less market appeal than expected and thelicenses may not be profitable; as well as any other risks that may befurther described in and the risk factors discussed in the Company'scontinuous disclosure including its Management's Discussion andAnalysis sections in its Quarterly Reports on Form 10-Q, AnnualReports on Form 10-K and Current Reports on Form 8-K filed under theCompany's profile at www.sec.gov.
Although management has attempted toidentify important risk factors that could cause actual results todiffer materially from those contained in the forward-lookinginformation in this presentation, there may be other risk factors notpresently known to the Company or that the Company presently believesare not material that could also cause actual results or future eventsto differ materially from those expressed in such forward-lookinginformation in this presentation. There can be no assurance that suchinformation will prove to be accurate, as actual results and futureevents could differ materially from those anticipated in suchinformation. Accordingly, readers and viewers should not place unduereliance on forward-looking information, which speaks only as of thedate made. The forward-looking information contained in this releaserepresents the Company’s expectations as of the date of this releaseor the date indicated, regardless of the time of delivery of thepresentation. The Company disclaims any intention, obligation orundertaking to update or revise any forward-looking information,whether as a result of new information, future events or otherwise,except as required under applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.